date,title,source
Oct-17-18,"Analysis: Positioning to Benefit within New York, KB Home, Sangamo Therapeutics, INTL FCStone, Maiden, and MobileIron  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Oct-18-18,Is Sangamo Therapeutics Inc. a Buy?,Motley Fool
Oct-29-18,What's in Store for Sangamo (SGMO) This Earnings Season?,Zacks
Nov-01-18,Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast,PR Newswire
Nov-06-18,Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences,PR Newswire
Nov-08-18,"Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-08-18,Sangamo Therapeutics Reports Third Quarter 2018 Financial Results,PR Newswire
Nov-14-18,Here's Why Sangamo Therapeutics Lost 12% Today,Motley Fool
Nov-14-18,Cutting-edge biotech Sangamo stock dives 13% after JPMorgan cites growing skepticism in downgrade,MarketWatch
Nov-14-18,Sangamo stock drops after J.P. Morgan downgrade,MarketWatch
Nov-15-18,"Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes",Zacks
Nov-15-18,Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites growing skepticism in downgrade,MarketWatch
Nov-20-18,Gilead's Vemlidy Gets Approval in China for HBV Infection,Zacks
Nov-26-18,"Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth",Zacks
Nov-28-18,"Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A.  Future Expectations, Projections Moving into 2018",GlobeNewswire
Dec-03-18,Sangamo Announces Completion Of TxCell Acquisition,PR Newswire
Dec-04-18,Gilead (GILD) Announces Data on CAR T Therapy Candidate,Zacks
Dec-04-18,Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company?,Simply Wall St.
Dec-11-18,Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO,Zacks
Dec-17-18,Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B,PR Newswire
Jan-04-19,Sangamo Therapeutics To Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-04-19,Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019,PR Newswire
Jan-08-19,Portfolios Making Up For Lost Time,Zacks
Jan-11-19,Top Picks 2019- Sangamo Therapeutics SGMO,MoneyShow
Jan-17-19,Cramer's lightning round: 'I'm not endorsing' Fiat Chrysler's stock anymore,CNBC
Jan-18-19,Here's How I Would Handle Speculative Sangamo Therapeutics,TheStreet.com
Jan-18-19,"Jim Cramer Advises His Viewers On Brink's, Medtronic And More",Benzinga
Jan-22-19,"Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development",PR Newswire
Jan-24-19,"Is Sangamo Therapeutics, Inc.s (NASDAQ:SGMO) CEO Salary Justified?",Simply Wall St.
Jan-29-19,"Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods  Discovering Underlying Factors of Influence",GlobeNewswire
Feb-01-19,Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I,PR Newswire
Feb-07-19,Why this East Bay biotech company shed half its value,American City Business Journals
Feb-07-19,Why Sangamo Therapeutics Crashed Today,Motley Fool
Feb-07-19,Sangamo Fails To Impress Investors With Genome Editing Studies,Benzinga
Feb-07-19,Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles,Bloomberg
Feb-07-19,Tests suggest scientists achieved 1st 'in body' gene editing,Associated Press
Feb-07-19,Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I,PR Newswire
Feb-07-19,Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913,PR Newswire
Feb-07-19,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",Benzinga
Feb-08-19,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",Benzinga
Feb-12-19,Biotech Stocks Rising,ACCESSWIRE
Feb-14-19,Is Moderna a Buy?,Motley Fool
Feb-19-19,What's in Store for Sangamo (SGMO) This Earnings Season?,Zacks
Feb-20-19,Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease,PR Newswire
Feb-21-19,Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast,PR Newswire
Feb-21-19,Analysts Estimate Sangamo Therapeutics (SGMO) to Report a Decline in Earnings: What to Look Out for,Zacks
Feb-21-19,"2 Frustrating Flops, Plus Welcome to the Wrinkle Wars",Motley Fool
Feb-21-19,"Investor Expectations to Drive Momentum within Sangamo Therapeutics, AVEO Pharmaceuticals, Everbridge, Huntington Ingalls Industries, Woodward, and SAP SE  Discovering Underlying Factors of Influence",GlobeNewswire
Feb-28-19,Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results,PR Newswire
Mar-04-19,Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT,Thomson Reuters StreetEvents
Mar-04-19,Why Sangamo Therapeutics Lost 22.9% of Its Value in February,Motley Fool
Mar-05-19,Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT,Thomson Reuters StreetEvents
Mar-06-19,Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences,PR Newswire
Mar-06-19,Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT,Thomson Reuters StreetEvents
Mar-07-19,5 Top Gene-Editing Stocks for 2019,Motley Fool
Mar-08-19,Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing,PR Newswire
Mar-12-19,"What Type Of Shareholder Owns Sangamo Therapeutics, Inc.s (NASDAQ:SGMO)?",Simply Wall St.
Mar-12-19,Signal Says Sell This Biotech Stock,Schaeffer's Investment Research
Mar-12-19,"Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy",PR Newswire
Mar-19-19,Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT,Thomson Reuters StreetEvents
Mar-25-19,S&P Holds Onto 2800 Despite Sharp Selloff,Zacks
Mar-25-19,"Report: Exploring Fundamental Drivers Behind M.D.C., salesforce.com, inc, Citrix, Match Group, Sangamo Therapeutics, and Popular  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Mar-26-19,Better Buy: Editas Medicine vs. Sangamo Therapeutics,Motley Fool
Mar-28-19,Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics,Motley Fool
Mar-29-19,Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology,PR Newswire
Apr-01-19,"Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update",PR Newswire
Apr-02-19,"Why Delta Air Lines, Sangamo Therapeutics, and Grayscale Bitcoin Trust Jumped Today",Motley Fool
Apr-02-19,Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A,Investor's Business Daily
Apr-02-19,Sangamo Soars Amid Multiple Development Pipeline Updates,Benzinga
Apr-02-19,Sangamo Therapeutics Bull Gap Fuels Hot Options Trading,Schaeffer's Investment Research
Apr-02-19,Sangamo Therapeutics News: Why SGMO Stock Is Soaring Today,InvestorPlace
Apr-02-19,Why Sangamo Therapeutics Stock Is Soaring Today,Motley Fool
Apr-02-19,Sangamo Stock Soars on Positive Hemophilia Treatment Trial,TheStreet.com
Apr-02-19,Sangamo's stock soars after upbeat trial data for hemophilia treatment,MarketWatch
Apr-02-19,Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data,PR Newswire
Apr-02-19,"Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio",PR Newswire
Apr-02-19,Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy,PR Newswire
Apr-02-19,Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy,Business Wire
